Biblio

Westeel V..  2019.  Active management of patient's comorbidities (including respiratory and cardiac comorbidities). RADIOTHERAPY AND ONCOLOGY. 133:S7-S8.

Roesch M., Mangin M., Bourtembourg A., Desmaret M., Maillet R., Ramanah R., Riethmuller D..  2015.  Active management of the second twin for vaginal delivery: Ruptured versus intact membranes. Apropos a series of 182 patients. JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION. 44:246-251.

Yi K, Ouisse M, Sadoulet-Reboul E, Matten G.  2019.  Active metamaterials with broadband controllable stiffness for tunable band gaps and non-reciprocal wave propagation. SMART MATERIALS AND STRUCTURES. 28:065025.

N. Van Long N, Joly C, Dantigny P.  2016.  Active packaging with antifungal activities. INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY. 220:73-90.

Zhu D., Ait-Amirat Y., N'Diaye A., Djerdir A..  2019.  Active thermal management between proton exchange membrane fuel cell and metal hydride hydrogen storage tank considering long-term operation. ENERGY CONVERSION AND MANAGEMENT. 202:112187.

Guinard E., C. Livideanu B, Barthelemy H., Viguier M., Reguiai Z., Richard M.A, Jullien D., Beneton N., Bara C., Vabres P. et al..  2016.  Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 30:1336-1341.

Dornaika F., Y. Traboulsi E, Ruicheck Y..  2019.  Active Two Phase Collaborative Representation Classifier for Image Categorization. IMAGE ANALYSIS AND PROCESSING - ICIAP 2019, PT I. 11751:175-184.

Meyer Y., Cumunel G..  2015.  Active vibration isolation with a MEMS device. Effects of nonlinearities on control efficiency. SMART MATERIALS AND STRUCTURES. 24:085004.

Liu Y-C, Laghrouche S, N'Diaye A, Cirrincione M.  2018.  Active-Flux-Based Super-Twisting Sliding Mode Observer for Sensorless Vector Control of Synchronous Reluctance Motor Drives. 2018 7TH INTERNATIONAL CONFERENCE ON RENEWABLE ENERGY RESEARCH AND APPLICATIONS (ICRERA). :402-406.

Schoffski P, Mir O, Kasper B, Papai Z, Blay J-Y, Italiano A, Benson C, Kopeckova K, Ali N, Dileo P et al..  2019.  Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.. JOURNAL OF CLINICAL ONCOLOGY. 37

Toulmonde M, Blay J-Y, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R et al..  2019.  Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. CLINICAL CANCER RESEARCH. 25:4611-4615.

Gassian N, Frontczak A, Mouillet G, Vernerey D, Manseur O, Goujon M, Meurisse A, Berthod D, Robert E, Calcagno F et al..  2020.  Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE. BULLETIN DU CANCER. 107:ES16-ES21.

Gassian N, Frontczak A, Mouillet G, Vernerey D, Manseur O, Goujon M, Meurisse A, Berthod D, Robert E, Calcagno F et al..  2020.  Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE. BULLETIN DU CANCER. 107:ES16-ES21.

Patsouris A., Septans A.L, Paillard M.J, Pivot X., Soibinet P., Jovenin N., Robert M., Gourmelon C., Korembaum C., Petit T. et al..  2015.  Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN). EUROPEAN JOURNAL OF CANCER. 51:S287.

Sanfilippo R, Hayward RL, Musoro J, Benson C, Leahy MGordon, Brunello A, Blay J-Y, Steeghs N, Desar IME, Ali N et al..  2020.  Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.. JOURNAL OF CLINICAL ONCOLOGY. 38

Moro-Sibilot D, Le Deley M-C, Zalcman G, Bota S, Sabatier R, Souquet PJean, Favier L, Poudenx M, Bombaron P, Audigier-Valette C et al..  2015.  Activity of Crizotinib in MET Amplified NSCLC: Preliminary Results of the AcSe Trial. JOURNAL OF THORACIC ONCOLOGY. 10:S178.

Moro-Sibilot D, Le Deley M-C, Zalcman G, Bota S, Sabatier R, Souquet PJean, Favier L, Poudenx M, Bombaron P, Audigier-Valette C et al..  2015.  Activity of Crizotinib in MET Amplified NSCLC: Preliminary Results of the AcSe Trial. JOURNAL OF THORACIC ONCOLOGY. 10:S178.

Vassal G, Ledeley M-C, Tournigand C, Aparicio T, Ray-Coquard I, Taillandier L, Escudier B, You B, Goncalves A, Bohas CLombard et al..  2015.  Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSe Program.. JOURNAL OF CLINICAL ONCOLOGY. 33

Albac S., Labrousse D., Hayez D., Anzala N., Bonnot D., Chavaneta P., Aslangul E., Croisier D..  2020.  Activity of Different Antistaphylococcal Therapies, A one or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 64:e01865-19.

Pouessel D, Terrisse SAarab, Mouillet G, Breitkopf K, Theodore C, Lobbedez FJoly, Roubaud G, Flechon A, Tourani J-M, Massard C et al..  2015.  Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C).. JOURNAL OF CLINICAL ONCOLOGY. 33

Jiang T, Soussignan R, Schaal B, Royet J-P.  2015.  Activity of neural reward circuits in response to food odors: an fMRI study of liking and wanting. CHEMICAL SENSES. 40:246.

Jiang T, Soussignan R, Schaal B, Royet J-P.  2015.  Activity of neural reward circuits in response to food odors: an fMRI study of liking and wanting. CHEMICAL SENSES. 40:246.

Herbst RS, Chau I, Petrylak DPeter, Arkenau H-T, Bendell JC, Santana-Davila R, Calvo E, Penel N, Martin-Liberal J, Soriano AO et al..  2018.  Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.. JOURNAL OF CLINICAL ONCOLOGY. 36

Mir O, Brodowicz T, Wallet J, Italiano A, Le Cesne A, Blay J-Y, Ryckewaert T, Bertucci F, Piperno-Neumann S, Ploner F et al..  2015.  Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a doubleblind, randomized placebo (PL) controlled phase II trial. JOURNAL OF CLINICAL ONCOLOGY. 33

Brodowicz T., Mir O., Wallet J., Italiano A., Le Cesne A., Blay J-I, Ryckewaert T., Bertucci F., Piperno-Neumann S., Ploner F. et al..  2016.  Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS) - results of a double-blind, randomized placebo (PL) controlled phase-II-trial. ONCOLOGY RESEARCH AND TREATMENT. 39:38.